Mometasone Furoate 0.1% – Medium‑Potency Classification and Clinical Use

Potency Classification

• Mometasone furoate 0.1 % ointment is classified as a medium‑potency (Class 4‑5) topical corticosteroid, not an upper‑middle potency agent (American Academy of Dermatology & National Psoriasis Foundation joint guideline). 1
• The 2021 Joint AAD‑NPF Guidelines categorize topical corticosteroids into seven potency classes based on vasoconstriction activity; mometasone furoate 0.1 % falls in the middle‑potency range (Class 4‑5). [1][2]
• Within the same potency class, mometasone furoate 0.1 % is grouped with other medium‑potency agents such as hydrocortisone valerate 0.2 %, fluocinolone acetonide 0.025 %, and triamcinolone acetonide 0.1 % (AAD‑NPF guideline). 1

Therapeutic Recommendations

• For initial treatment of adults with psoriasis or atopic dermatitis, corticosteroids of classes 2‑5 (moderate to high potency) are generally recommended; mometasone furoate 0.1 % meets this criterion. (AAD‑NPF guideline). [2][4]
• Medium‑potency steroids such as mometasone can be employed for longer treatment courses than high‑ or very‑high‑potency agents because they have a more favorable adverse‑event profile (expert consensus). 3
• Mometasone furoate 0.1 % is suitable for intermittent maintenance therapy (e.g., twice weekly) to reduce disease flares (clinical practice recommendation). 3

Formulation Considerations

• Although ointment vehicles provide better skin penetration than creams, the formal potency classification of mometasone furoate 0.1 % remains medium‑potency regardless of the vehicle (AAD‑NPF guideline). 1

Strength of evidence: The cited guidelines do not specify a numeric evidence grade for these statements; they are based on expert consensus and guideline committee review.